{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:01:59Z","timestamp":1790200919117,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470368"],"award-info":[{"award-number":["81470368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670187"],"award-info":[{"award-number":["81670187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81641011"],"award-info":[{"award-number":["81641011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7152030"],"award-info":[{"award-number":["7152030"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7172047"],"award-info":[{"award-number":["7172047"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special","doi-asserted-by":"crossref","award":["2018-1-2151"],"award-info":[{"award-number":["2018-1-2151"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0584-6","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:21:49Z","timestamp":1522801309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Cunzhen","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"584_CR1","doi-asserted-by":"crossref","unstructured":"Dreyling M, Geisler C, Hermine O, Kluin-Nelemans H C, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014, 25 Suppl 3:iii83\u2013iii92.","DOI":"10.1093\/annonc\/mdu264"},{"issue":"8","key":"584_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806\u201313.","journal-title":"Am J Hematol"},{"issue":"6","key":"584_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"30","key":"584_CR4","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"584_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520\u20135.","journal-title":"Ann Oncol"},{"issue":"29","key":"584_CR6","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395.","journal-title":"J Clin Oncol"},{"issue":"11","key":"584_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","volume":"24","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Vose JM, Czuczman MS, Reeder CB, Haioun C, Polikoff J, Tilly H, Zhang L, Prandi K, Li J, et al. Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24(11):2892\u20137.","journal-title":"Ann Oncol"},{"issue":"23","key":"584_CR8","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"584_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","volume":"19","author":"RD Cassaday","year":"2013","unstructured":"Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(9):1403\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"584_CR10","first-page":"647","volume":"5","author":"DK Graham","year":"1994","unstructured":"Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ. 1994;5(6):647\u201357.","journal-title":"Cell Growth Differ"},{"issue":"19","key":"584_CR11","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-12-1451","volume":"19","author":"CT Cummings","year":"2013","unstructured":"Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res. 2013;19(19):5275\u201380.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"584_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1172\/JCI67816","volume":"123","author":"J Schlegel","year":"2013","unstructured":"Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest. 2013;123(5):2257\u201367.","journal-title":"J Clin Invest"},{"issue":"4","key":"584_CR13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/pcmr.12110","volume":"26","author":"KA Tworkoski","year":"2013","unstructured":"Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res. 2013;26(4):527\u201341.","journal-title":"Pigment Cell Melanoma Res"},{"key":"584_CR14","doi-asserted-by":"crossref","unstructured":"Yi JH, Jang J, Cho J, Do IG, Hong M, Kim ST, Kim KM, Lee S, Park SH, Park JO. MerTK is a novel therapeutic target in gastric cancer. Oncotarget. 2017;8(57):96656-67.","DOI":"10.18632\/oncotarget.3750"},{"issue":"9","key":"584_CR15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2013-01-478156","volume":"122","author":"RM Linger","year":"2013","unstructured":"Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandao LN, Winges A, Sawczyn KK, Liang X, et al. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 2013;122(9):1599\u2013609.","journal-title":"Blood"},{"issue":"46","key":"584_CR16","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1038\/onc.2013.40","volume":"32","author":"AB Lee-Sherick","year":"2013","unstructured":"Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2013;32(46):5359\u201368.","journal-title":"Oncogene"},{"key":"584_CR17","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1038\/bcj.2012.46","volume":"3","author":"LN Brandao","year":"2013","unstructured":"Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, et al. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J. 2013;3:e101.","journal-title":"Blood Cancer J"},{"issue":"11","key":"584_CR18","doi-asserted-by":"publisher","first-page":"9206","DOI":"10.18632\/oncotarget.3280","volume":"6","author":"S Xie","year":"2015","unstructured":"Xie S, Li Y, Li X, Wang L, Yang N, Wang Y, Wei H. Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib. Oncotarget. 2015;6(11):9206\u201319.","journal-title":"Oncotarget"},{"key":"584_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","volume":"100","author":"RM Linger","year":"2008","unstructured":"Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35\u201383.","journal-title":"Adv Cancer Res"},{"issue":"11","key":"584_CR20","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1158\/1535-7163.MCT-13-0040","volume":"12","author":"S Christoph","year":"2013","unstructured":"Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013;12(11):2367\u201377.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"584_CR21","doi-asserted-by":"publisher","first-page":"32678","DOI":"10.18632\/oncotarget.8724","volume":"7","author":"A von Massenhausen","year":"2016","unstructured":"von Massenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schrock A, Bootz F, et al. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget. 2016;7(22):32678\u201394.","journal-title":"Oncotarget"},{"issue":"16","key":"584_CR22","doi-asserted-by":"publisher","first-page":"7031","DOI":"10.1021\/jm500749d","volume":"57","author":"W Zhang","year":"2014","unstructured":"Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, et al. UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor. J Med Chem. 2014;57(16):7031\u201341.","journal-title":"J Med Chem"},{"issue":"6","key":"584_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/1078-0432.CCR-16-1330","volume":"23","author":"D DeRyckere","year":"2017","unstructured":"DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GG, Eryildiz F, Montgomery SA, et al. UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clin Cancer Res. 2017;23(6):1481\u201392.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"584_CR24","first-page":"4398","volume":"62","author":"S Ek","year":"2002","unstructured":"Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 2002;62(15):4398\u2013405.","journal-title":"Cancer Res"},{"issue":"1","key":"584_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ijc.31044","volume":"142","author":"J Li","year":"2018","unstructured":"Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, et al. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton\u2019s tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. Int J Cancer. 2018;142(1):202\u201313.","journal-title":"Int J Cancer"},{"key":"584_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"issue":"7380","key":"584_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nature10661","volume":"481","author":"KJ Png","year":"2012","unstructured":"Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2012;481(7380):190\u20134.","journal-title":"Nature"},{"issue":"17","key":"584_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/sj.onc.1201039","volume":"14","author":"J Chen","year":"1997","unstructured":"Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene. 1997;14(17):2033\u20139.","journal-title":"Oncogene"},{"issue":"1","key":"584_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mcn.2006.06.011","volume":"33","author":"D Prasad","year":"2006","unstructured":"Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, Lemke G. TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci. 2006;33(1):96\u2013108.","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"584_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","volume":"129","author":"JH Myklebust","year":"2017","unstructured":"Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Walchli S, Green MR, Troen G, Liestol K, Beiske K, et al. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood. 2017;129(6):759\u201370.","journal-title":"Blood"},{"issue":"1","key":"584_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26\u201338.","journal-title":"Blood"},{"issue":"5","key":"584_CR32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, Quintanilla-Martinez L, Raffeld M. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108(5):1668\u201376.","journal-title":"Blood"},{"issue":"4","key":"584_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/ijc.2910380413","volume":"38","author":"JV Melo","year":"1986","unstructured":"Melo JV, Brito-Babapulle V, Foroni L, Robinson DS, Luzzatto L, Catovsky D. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer. 1986;38(4):531\u20138.","journal-title":"Int J Cancer"},{"issue":"38","key":"584_CR34","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1038\/onc.2011.588","volume":"31","author":"AE Rogers","year":"2012","unstructured":"Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM, Keating AK. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 2012;31(38):4171\u201381.","journal-title":"Oncogene"},{"issue":"7","key":"584_CR35","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/onc.2012.104","volume":"32","author":"Y Wang","year":"2013","unstructured":"Wang Y, Moncayo G, Morin P Jr, Xue G, Grzmil M, Lino MM, Clement-Schatlo V, Frank S, Merlo A, Hemmings BA. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene. 2013;32(7):872\u201382.","journal-title":"Oncogene"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0584-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:20:56Z","timestamp":1553026856000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0584-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by review board of the Peking University Cancer Hospital & Institute. Patients\u2019 samples were collected after informed consent in accordance with the Declaration of Helsinki. Animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, which were approved by the Peking University Cancer Hospital & Institute.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"43"}}